Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Alvotech

ALVOWNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.30
$0.14(84.50%)
U.S. Market opens in 15h 43m

Alvotech Fundamental Analysis

Alvotech (ALVOW) shows moderate financial fundamentals with a PE ratio of 18.03, profit margin of 12.17%, and ROE of -26.11%. The company generates $0.6B in annual revenue with moderate year-over-year growth of 4.36%.

Key Strengths

Cash Position50.97%

Areas of Concern

ROE-26.11%
Operating Margin7.61%
PEG Ratio2.16
We analyze ALVOW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 86.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B+
86.4/100

We analyze ALVOW's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALVOW struggles to generate sufficient returns from assets.

ROA > 10%
4.93%

Valuation Score

Moderate

ALVOW shows balanced valuation metrics.

PE < 25
18.03
PEG Ratio < 2
2.16

Growth Score

Moderate

ALVOW shows steady but slowing expansion.

Revenue Growth > 5%
4.36%
EPS Growth > 10%
64.20%

Financial Health Score

Excellent

ALVOW maintains a strong and stable balance sheet.

Debt/Equity < 1
-7.25
Current Ratio > 1
1.42

Profitability Score

Weak

ALVOW struggles to sustain strong margins.

ROE > 15%
-2611.20%
Net Margin ≥ 15%
12.17%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALVOW Expensive or Cheap?

P/E Ratio

ALVOW trades at 18.03 times earnings. This indicates a fair valuation.

18.03

PEG Ratio

When adjusting for growth, ALVOW's PEG of 2.16 indicates potential overvaluation.

2.16

Price to Book

The market values Alvotech at -7.09 times its book value. This may indicate undervaluation.

-7.09

EV/EBITDA

Enterprise value stands at 0.85 times EBITDA. This is generally considered low.

0.85

How Well Does ALVOW Make Money?

Net Profit Margin

For every $100 in sales, Alvotech keeps $12.17 as profit after all expenses.

12.17%

Operating Margin

Core operations generate 7.61 in profit for every $100 in revenue, before interest and taxes.

7.61%

ROE

Management delivers $-26.11 in profit for every $100 of shareholder equity.

-26.11%

ROA

Alvotech generates $4.93 in profit for every $100 in assets, demonstrating efficient asset deployment.

4.93%

Following the Money - Real Cash Generation

Operating Cash Flow

Alvotech generates limited operating cash flow of $-26.43M, signaling weaker underlying cash strength.

$-26.43M

Free Cash Flow

Alvotech generates weak or negative free cash flow of $-113.22M, restricting financial flexibility.

$-113.22M

FCF Per Share

Each share generates $-0.38 in free cash annually.

$-0.38

FCF Yield

ALVOW converts -8.82% of its market value into free cash.

-8.82%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

18.03

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

2.16

vs 25 benchmark

P/B Ratio

Price to book value ratio

-7.09

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.28

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-7.25

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.42

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.26

vs 25 benchmark

ROA

Return on assets percentage

0.05

vs 25 benchmark

ROCE

Return on capital employed

0.04

vs 25 benchmark

How ALVOW Stacks Against Its Sector Peers

MetricALVOW ValueSector AveragePerformance
P/E Ratio18.0329.43 Better (Cheaper)
ROE-26.11%800.00% Weak
Net Margin12.17%-20145.00% (disorted) Strong
Debt/Equity-7.250.30 Strong (Low Leverage)
Current Ratio1.424.64 Neutral
ROA4.93%-17936.00% (disorted) Weak

ALVOW outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alvotech's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

1295.18%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-0.47%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-143.24%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ